Hypera S.A. (BVMF:HYPE3)
Brazil · Delayed Price · Currency is BRL | Market Cap | 14.01B +13.0% |
| Revenue (ttm) | 7.70B +3.4% |
| Net Income | 1.20B -10.9% |
| EPS | 1.88 -10.2% |
| Shares Out | 632.95M |
| PE Ratio | 11.78 |
| Forward PE | 7.94 |
| Dividend | 1.17 (5.28%) |
| Ex-Dividend Date | Dec 29, 2025 |
| Volume | 4,537,000 |
| Average Volume | 3,377,610 |
| Open | 22.19 |
| Previous Close | 22.31 |
| Day's Range | 21.90 - 22.39 |
| 52-Week Range | 18.69 - 28.87 |
| Beta | 0.20 |
| RSI | 43.75 |
| Earnings Date | Mar 12, 2026 |
About Hypera
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, an... [Read more]
Financial Performance
In 2025, Hypera's revenue was 7.70 billion, an increase of 3.45% compared to the previous year's 7.44 billion. Earnings were 1.20 billion, a decrease of -10.86%.
Financial StatementsNews
Brazil's Hypera announces new majority stakeholder group
Brazilian drugmaker Hypera said on Monday that shareholders executed an agreement by which a new control group now holds 53% of share capital.